Investigational Drug Information for ASP015K
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for ASP015K?
ASP015K is an investigational drug.
There have been 32 clinical trials for ASP015K.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 25th 2014.
The most common disease conditions in clinical trials are Arthritis, Arthritis, Rheumatoid, and Psoriasis. The leading clinical trial sponsors are Astellas Pharma Inc, Astellas Pharma Global Development, Inc., and Janssen Biotech, Inc.
There are eighty US patents protecting this investigational drug and one international patent.
Summary for ASP015K
| US Patents | 80 |
| International Patents | 1,058 |
| US Patent Applications | 417 |
| WIPO Patent Applications | 386 |
| Japanese Patent Applications | 151 |
| Clinical Trial Progress | Phase 3 (2014-07-25) |
| Vendors | 28 |
Recent Clinical Trials for ASP015K
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects | Astellas Pharma China, Inc. | Phase 1 |
| A Study to Assess Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX) | Astellas Pharma China, Inc. | Phase 3 |
| A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Metformin | Astellas Pharma Inc | Phase 1 |
Clinical Trial Summary for ASP015K
Top disease conditions for ASP015K
Top clinical trial sponsors for ASP015K
US Patents for ASP015K
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ASP015K | ⤷ Try a Trial | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (Foster City, CA) | ⤷ Try a Trial |
| ASP015K | ⤷ Try a Trial | Kinase inhibitors | Respivert Limited (High Wycombe, Buckinghamshire, GB) Topivert Pharma Limited (London, GB) | ⤷ Try a Trial |
| ASP015K | ⤷ Try a Trial | Substituted indazoles for treating tendon and/or ligament injuries | NOVARTIS AG (Basel, CH) | ⤷ Try a Trial |
| ASP015K | ⤷ Try a Trial | Kinase inhibitors | Respivert Limited (N/A) Topivert Pharma Limited (London, GB) | ⤷ Try a Trial |
| ASP015K | ⤷ Try a Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ASP015K
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ASP015K | Argentina | AR108926 | 2036-06-30 | ⤷ Try a Trial |
| ASP015K | Australia | AU2017289158 | 2036-06-30 | ⤷ Try a Trial |
| ASP015K | Canada | CA3029457 | 2036-06-30 | ⤷ Try a Trial |
| ASP015K | European Patent Office | EP3478674 | 2036-06-30 | ⤷ Try a Trial |
| ASP015K | Spain | ES2800339 | 2036-06-30 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
